Table 5 Summary of the studies conducted on the application of commonly investigated circRNAs as biomarkers in solid tumors
Malignancy | CircRNA | Target | N. of cases | Pattern of alteration | Application | Site of measurement | Validity | Associated determinants of prognosis | Additional information | References |
|---|---|---|---|---|---|---|---|---|---|---|
Lung adenocarcinoma | Hsa_circ_0070661 | TEK | 38 | Up-regulation | Prognostic | Serum | – | – | Hsa_circ_0070661 inhibits cancer progression through miR-556-5p/TEK axis in lung adenocarcinoma | [187] |
Circ_0001058 | TEK |  | Up-regulation | Prognostic | Serum | – | – | Circ_0001058 represses the progression of lung adenocarcinoma through governing of the miR-486-5p/TEK signaling axis | [188] | |
circ7312 | EGFR-TKI | 89 | Up-regulation | Prognostic, treatment response | Tumor tissue | – | DFS and OS were significantly longer in LUAD patients with low circ7312 than in those with high circ7312 expression(p = 0.0043 and p = 0.0099) | Hsa_circ_0007312 Promotes Third-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance through Pyroptosis and Apoptosis via the MiR-764/MAPK1 Axis in Lung Adenocarcinoma Cells. J Cancer | [201] | |
circ-0003748 | EGFR-TKI | 23 | Up-regulation | Prognostic | Plasma | – | – | Construction of a circRNA-miRNA-mRNA Regulated Pathway Involved in EGFR-TKI Lung Adenocarcinoma Resistance | [238] | |
circ-0001398 | EGFR-TKI | 23 | Up-regulation | Prognostic | Plasma | – | – | Construction of a circRNA-miRNA-mRNA Regulated Pathway Involved in EGFR-TKI Lung Adenocarcinoma Resistance | [238] | |
hsa_circ_0005576 | IGF1R | 20 (mice) | Up-regulation | Prognostic, treatment response | Tumor tissue | – | – | Hsa_circ_0005576 promotes osimertinib resistance through the miR-512-5p/IGF1R axis in lung adenocarcinoma cells | [203] | |
hsa_circ_0012673 | ERBB3 | 33 | Up-regulation | Prognostic |  | – | – | Increased circular RNA hsa_circ_0012673 acts as a sponge of miR-22 to promote lung adenocarcinoma proliferation | [189] | |
NSCLC | Circ_0014235 | EGFR-TKI | 24 (mice) | Up-regulation | Treatment response | Tumor cells | – | – | Circ_0014235 confers Gefitinib resistance and malignant behaviors in non-small cell lung cancer resistant to Gefitinib by governing the miR-146b-5p/YAP/PD-L1 pathway | [202] |
circRNA_102481 | ROR1 | 58 | Up-regulation | Diagnostic, treatment response | Serum | – | High expression of circRNA_1024810 in exosomes was closely associated with brain metastasis (P < 0.05) | Tumor-derived exosomal circRNA_102481 contributes to EGFR-TKIs resistance via the miR-30a-5p/ROR1 axis in non-small cell lung cancer | [196] | |
hsa_circ_0109320 | EGFR-TKI | 52 | Up-regulation | Diagnostic, treatment response | Plasma | AUC = 0.81 | Elevated hsa_circ_0109320 expression was associated with significantly better PFS in patients with NSCLC after gefitinib treatment(p = 0.02) | Circular RNA profiling identified as a biomarker for predicting the efficacy of Gefitinib therapy for non-small cell lung cancer | [205] | |
Lung cancer | circ-ERBB2 | ERBB2 | 31 | Up-regulation | Diagnostic, treatment response | Cancer tissue | – | – | Propofol suppresses lung cancer tumorigenesis by modulating the circ-ERBB2/miR-7-5p/FOXM1 axis | [204] |
Glioma | circFAM53B | c-met | 40 | Up-regulation | Treatment response | Glioma cells | – | Higher circFAM53B levels were linked to poorer survival of glioma patients (p = 0.0441) | CircFAM53B promotes the proliferation and metastasis of glioma through activating the c-MET/PI3K/AKT pathway via sponging miR-532-3p | [190] |
Circ_0001588 | EPHB4 |  | Up-regulation | Prognostic |  | – | – | . Circ_0001588 Upregulates ERBB4 to Promote Glioma Malignant Progression Through Sponging miR-1281 | [191] | |
circ_0001162 | EPHB4 | 30 | Up-regulation | Prognostic | Glioma cells | – | – | circ_0001162 promotes cell proliferation and invasion of glioma via the miR-936/ERBB4 axis | [192] | |
hsa_circ_0081519 | EPHB4 | 40 | Up-regulation | Prognostic, treatment response | Glioma cells | – | Higher circEPHB4 or SOX10 level was independently correlated with reduced overall survival(p < 0.05) | . CircRNA EPHB4 modulates stem properties and proliferation of gliomas via sponging miR-637 and up-regulating SOX10 | [193] | |
Laryngeal squamous cell carcinoma | Circ_0044520 | ROR2 | 60 | Up-regulation | Prognostic, treatment response | – | - | circ_0044520 was correlated with tumor size, clinical stage, and lymphoid node metastasis(p < 0.05) | . Circ_0044520 regulates the progression of laryngeal squamous cell carcinoma via the miR-338-3p/ROR2 axis | [194] |
Ovarian cancer | circ_0000745 | ERBB4 | 50 | Up-regulation | Prognostic, treatment response | Tumor tissue | – | – | . RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells | [199] |
Gastric cancer | hsa_circ_0006470 | ROR1 |  | Up-regulation | Diagnosis, treatment response | Cancer cells | – | – | circRNA_0006470 promotes the proliferation and migration of gastric cancer cells by functioning as a sponge of miR-27b-3p | [195] |
PTC | circ_0079558 | MET | 30 | Up-regulation | Diagnostic | Tumor tissues | – | – | Circ_0079558 promotes papillary thyroid cancer progression by binding to miR-26b-5p to activate MET/AKT signaling | [198] |
Colorectal cancer | circ-NSD2 | DDR1 |  | Up-regulation | Prognostic, treatment response |  | – | – | NSD2 circular RNA promotes metastasis of colorectal cancer by targeting miR-199b-5p-mediated DDR1 and JAG1 signalling | [197] |
T-cell lymphoblastic lymphoma | circ-LAMP1 | DDR2 | 34 | Up-regulation | Prognostic | T-LBL tissue | – | – | Circ-LAMP1 promotes T-cell lymphoblastic lymphoma progression via acting as a ceRNA for miR-615-5p to regulate DDR2 expression | [200] |